No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
NVAX250110C14500
- 0.05
- -0.04-44.44%
15min DelayClose Jan 7 16:00 ET
0.13High0.05Low
0.09Open0.09Pre Close230 Volume0 Open Interest14.50Strike Price1.90KTurnover223.36%IV34.47%PremiumJan 10, 2025Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0868Delta0.0730Gamma135.25Leverage Ratio-0.0511Theta0.0001Rho11.74Eff Leverage0.0015Vega
Intraday
- 5D
- Daily
News
Options Alert: Why Novavax (NVAX) Could Be the Biotech Hero of Trump 2.0
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death -- Barrons.com
Why Novavax (NVAX) Stock Is Rising
Shares of Vaccine Makers Are Trading Higher After the First Bird Flu Death Was Reporting in the US. Additionally, a Recent DCD Report Noted an Increase in Acute Respiratory Illness Activity.